Supporting Research | Womei Biology Customer Paper Reward Program_Latest Activities_News

preamble

Since its establishment, Womei Bio has been committed to providing high-quality products for the majority of scientific research users. In order to thank the majority of researchers for their continuous support and love to Womei Bio, our company has decided to reward the researchers who use our products to publish high quality academic articles since June 01, 2022, the specific program is as follows.

Ⅰ

Targets of incentives

All researchers and students who use Womei Bio's products and indicate in the text the correct name of the product used and the name of the company "Suzhou Womei Biology CO,.Ltd" "Womei Bio" (or "Suzhou Womei Biology CO,.Ltd" "Womei Bio") are entitled to apply for the award (see Table 1). "Ltd" "Womei Bio") are authorized to apply for the award (see Table 1).

Ⅱ

Reward Scope

The award will be given to the first author or the corresponding author of the included article himself/herself, and the award payment will be applied by the first author or the corresponding author (only one person can apply for the award), and each article can only be applied once.

Ⅲ

Reward Criteria

Reward 300 RMB or 600 RMB worth of media products for each Chinese version paper published; reward 500 RMB or 1000 RMB worth of media products for each English version paper published, or credit the corresponding amount in the subsequent purchase of products.

Ⅳ

Selection and award procedures

Before December 31 every year, the first author himself/herself will fill in and submit the application form, and after the company examines and approves it, the bonus will be paid directly to the individual by Womei Bio after deducting the personal income tax, and after the first author receives the bonus, it will be distributed in accordance with the contribution of the authors of the paper and the size of the responsibility.

Applying for a Womei Bio paper award implicitly assumes that Womei Bio owns the publicity rights to the text.

Send the application form with the complete paper (in pdf format), the front and back of the applicant's ID card as well as the front and back of his/her bank card to womeishengwu@szwmbio.com and state in the subject of the email that you are applying for an award for publishing a scientific paper.

After our review and approval, we will contact the applicant as soon as possible to determine the delivery method and address.

table1

640

end

Suzhou Womei Biology CO,.Ltd is a core supplier in the domestic biologics industry, providing personalized culture media, bioreactors, immune adjuvants, biochemical reagents, etc., as well as providing supporting services such as formulation production, process optimization, process validation and technical support for the biopharmaceutical industry.

Womei Bio's founding team and R&D core positions come from former faculty members and outstanding graduates of the State Key Laboratory of Bioreactors at the East China University of Science and Technology, with more than three decades of technological deposits and application accumulations in the fields of animal cell culture engineering and bioreactor engineering.

In 2020, in order to promote the comprehensive upgrade of process development, quality system, management system and production capacity, Womei Bio signed a contract with Zhangjiagang City, Suzhou, to start the construction of a new factory project including culture media, bioreactor manufacturing, bioreactor fermentation, etc., with a total area of 13,000 square meters, of which 50% is a GMP standard factory. After the completion of the construction, it will be able to realize the processing of low-temperature needle milling powder of more than 100,000 liters in a single batch, with a total production capacity of more than 10 million liters. Twelve bioreactor production stations have been built, which can realize the production requirements of the largest 10-ton bioreactor. In addition, supporting the construction of 500 to 5000 liters of modern high-tech bioreactor product display line.

Since 2009, Womei Bio has been serving biologics companies for more than ten years, of which the market share of products in the animal vaccine industry is among the top, and only the technical service has accumulated nearly one hundred million dollars in contracts.

Relying on its strong R&D team, Womei Bio has initially completed the layout of upstream and downstream process solutions for biopharmaceuticals. In the future, Womei Bio will strive to become a comprehensive service provider to provide complete solutions for the domestic biopharmaceutical field.Womei Bio will provide more high-quality technical services for China's antibody, vaccine, cellular therapy enterprises, to support the development of China's antibodies, vaccines, cellular therapy and other innovative biopharmaceutical products.